TABLE S1 Uptake of [^{3}H]doravirine in human hepatocytes

Substrate	Time (min)	Without inhibitors (pmol/10^6 cells/min)	With inhibitors (pmol/10^6 cells/min)
[^{3}H]$E_2$17βG	5	37.7 ± 2.2	7.5 ± 0.3
[^{3}H]CCK8	5	0.023 ± 0.001	0.006 ± 0.000
[^{3}H]TCA	5	169.6 ± 3.2	13.5 ± 0.7
[^{14}C]TEA	5	8.7 ± 0.1	2.2 ± 0.1
Doravirine	0	17.4 ± 0.6	16.0 ± 0.5
	1	65.7 ± 2.4	52.6 ± 3.3
	2	80.1 ± 1.8	61.1 ± 0.5
	5	91.9 ± 2.5	67.1 ± 1.7

[^{3}H]$E_2$17βG (1 μM), [^{3}H]CCK8 (5 nM), [^{3}H]TCA (1 μM) and [^{14}C]TEA (1 μM) were used as control substrates and CsA (10 μM), rifamycin SV (10 μM), rifampin (100 μM) and quinidine (50 μM) as inhibitors.

Mean ± SEM values are listed (n=3).

CCK8, cholecystokinin-8; CsA, cyclosporine A; $E_2$17βG, estradiol 17β-glucuronide; TCA, taurocholic acid; TEA, tetraethylammonium.